Results of treatment of inferior vena cava syndrome with expandable metallic stents

William S. Fletcher, Paul C. Lakin, Rodney Pommier, Thea Wilmarth

    Research output: Contribution to journalArticle

    51 Citations (Scopus)

    Abstract

    Background: Patients with hepatic metastases often develop obstruction of the intrahepatic inferior vena cava (IVC), known as IVC syndrome. This obstruction is debilitating due to the development of ascites and anasarca. Objectives: To update our experience in the diagnosis and treatment of IVC syndrome and to evaluate the efficacy of expandable stents in the treatment of IVC syndrome. Design: Retrospective review. Setting: University hospital. Patients: Twenty-eight patients with hepatic metastases diagnosed as having IVC syndrome. Intervention: Patients underwent transfemoral placement of Gianturco-Rosch self-expandable Z metallic stents in the intrahepatic IVC. One patient was treated with a Wallstent. Stents were 15 to 25 mm in diameter and 60 to 140 mm in length. Pressure gradients across the IVC were measured before and after stent placement in all patients. Main Outcome Measures: Change in pressure gradient, relief of ascites and anasarca, loss of weight, patency of the primary stent, and survival after stent placement. Results: Pressure gradients were reduced in all patients, which was followed by rapid reduction of ascites and anasarca with a median weight loss of 5.85 kg. Survival after stent placement varied from 1 to 99 days, with a mean of 34 days. Stent patency remained until death in all patients. Conclusion: The debilitation of IVC syndrome due to ascites and anasarca can be considerably palliated by placement of transfemoral percutaneous stents.

    Original languageEnglish (US)
    Pages (from-to)935-938
    Number of pages4
    JournalArchives of Surgery
    Volume133
    Issue number9
    DOIs
    StatePublished - Sep 1998

    Fingerprint

    Inferior Vena Cava
    Stents
    Ascites
    Edema
    Therapeutics
    Pressure
    Weight Loss
    Neoplasm Metastasis
    Survival
    Liver
    Outcome Assessment (Health Care)

    ASJC Scopus subject areas

    • Surgery

    Cite this

    Results of treatment of inferior vena cava syndrome with expandable metallic stents. / Fletcher, William S.; Lakin, Paul C.; Pommier, Rodney; Wilmarth, Thea.

    In: Archives of Surgery, Vol. 133, No. 9, 09.1998, p. 935-938.

    Research output: Contribution to journalArticle

    Fletcher, William S. ; Lakin, Paul C. ; Pommier, Rodney ; Wilmarth, Thea. / Results of treatment of inferior vena cava syndrome with expandable metallic stents. In: Archives of Surgery. 1998 ; Vol. 133, No. 9. pp. 935-938.
    @article{ec5221d0fadc4c7291136ffff67ae307,
    title = "Results of treatment of inferior vena cava syndrome with expandable metallic stents",
    abstract = "Background: Patients with hepatic metastases often develop obstruction of the intrahepatic inferior vena cava (IVC), known as IVC syndrome. This obstruction is debilitating due to the development of ascites and anasarca. Objectives: To update our experience in the diagnosis and treatment of IVC syndrome and to evaluate the efficacy of expandable stents in the treatment of IVC syndrome. Design: Retrospective review. Setting: University hospital. Patients: Twenty-eight patients with hepatic metastases diagnosed as having IVC syndrome. Intervention: Patients underwent transfemoral placement of Gianturco-Rosch self-expandable Z metallic stents in the intrahepatic IVC. One patient was treated with a Wallstent. Stents were 15 to 25 mm in diameter and 60 to 140 mm in length. Pressure gradients across the IVC were measured before and after stent placement in all patients. Main Outcome Measures: Change in pressure gradient, relief of ascites and anasarca, loss of weight, patency of the primary stent, and survival after stent placement. Results: Pressure gradients were reduced in all patients, which was followed by rapid reduction of ascites and anasarca with a median weight loss of 5.85 kg. Survival after stent placement varied from 1 to 99 days, with a mean of 34 days. Stent patency remained until death in all patients. Conclusion: The debilitation of IVC syndrome due to ascites and anasarca can be considerably palliated by placement of transfemoral percutaneous stents.",
    author = "Fletcher, {William S.} and Lakin, {Paul C.} and Rodney Pommier and Thea Wilmarth",
    year = "1998",
    month = "9",
    doi = "10.1001/archsurg.133.9.935",
    language = "English (US)",
    volume = "133",
    pages = "935--938",
    journal = "JAMA Surgery",
    issn = "2168-6254",
    publisher = "American Medical Association",
    number = "9",

    }

    TY - JOUR

    T1 - Results of treatment of inferior vena cava syndrome with expandable metallic stents

    AU - Fletcher, William S.

    AU - Lakin, Paul C.

    AU - Pommier, Rodney

    AU - Wilmarth, Thea

    PY - 1998/9

    Y1 - 1998/9

    N2 - Background: Patients with hepatic metastases often develop obstruction of the intrahepatic inferior vena cava (IVC), known as IVC syndrome. This obstruction is debilitating due to the development of ascites and anasarca. Objectives: To update our experience in the diagnosis and treatment of IVC syndrome and to evaluate the efficacy of expandable stents in the treatment of IVC syndrome. Design: Retrospective review. Setting: University hospital. Patients: Twenty-eight patients with hepatic metastases diagnosed as having IVC syndrome. Intervention: Patients underwent transfemoral placement of Gianturco-Rosch self-expandable Z metallic stents in the intrahepatic IVC. One patient was treated with a Wallstent. Stents were 15 to 25 mm in diameter and 60 to 140 mm in length. Pressure gradients across the IVC were measured before and after stent placement in all patients. Main Outcome Measures: Change in pressure gradient, relief of ascites and anasarca, loss of weight, patency of the primary stent, and survival after stent placement. Results: Pressure gradients were reduced in all patients, which was followed by rapid reduction of ascites and anasarca with a median weight loss of 5.85 kg. Survival after stent placement varied from 1 to 99 days, with a mean of 34 days. Stent patency remained until death in all patients. Conclusion: The debilitation of IVC syndrome due to ascites and anasarca can be considerably palliated by placement of transfemoral percutaneous stents.

    AB - Background: Patients with hepatic metastases often develop obstruction of the intrahepatic inferior vena cava (IVC), known as IVC syndrome. This obstruction is debilitating due to the development of ascites and anasarca. Objectives: To update our experience in the diagnosis and treatment of IVC syndrome and to evaluate the efficacy of expandable stents in the treatment of IVC syndrome. Design: Retrospective review. Setting: University hospital. Patients: Twenty-eight patients with hepatic metastases diagnosed as having IVC syndrome. Intervention: Patients underwent transfemoral placement of Gianturco-Rosch self-expandable Z metallic stents in the intrahepatic IVC. One patient was treated with a Wallstent. Stents were 15 to 25 mm in diameter and 60 to 140 mm in length. Pressure gradients across the IVC were measured before and after stent placement in all patients. Main Outcome Measures: Change in pressure gradient, relief of ascites and anasarca, loss of weight, patency of the primary stent, and survival after stent placement. Results: Pressure gradients were reduced in all patients, which was followed by rapid reduction of ascites and anasarca with a median weight loss of 5.85 kg. Survival after stent placement varied from 1 to 99 days, with a mean of 34 days. Stent patency remained until death in all patients. Conclusion: The debilitation of IVC syndrome due to ascites and anasarca can be considerably palliated by placement of transfemoral percutaneous stents.

    UR - http://www.scopus.com/inward/record.url?scp=0031683112&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0031683112&partnerID=8YFLogxK

    U2 - 10.1001/archsurg.133.9.935

    DO - 10.1001/archsurg.133.9.935

    M3 - Article

    VL - 133

    SP - 935

    EP - 938

    JO - JAMA Surgery

    JF - JAMA Surgery

    SN - 2168-6254

    IS - 9

    ER -